Overview

Bioglutide (NA-931) is an investigational small synthetic peptide-like molecule from Biomed Industries, reportedly derived from a cyclic IGF-1 fragment. It is described as the first 'quadruple' agonist, simultaneously engaging the receptors for insulin-like growth factor 1 (IGF-1R), glucagon-like peptide-1 (GLP-1R), glucose-dependent insulinotropic polypeptide (GIPR) and glucagon (GCGR). This contrasts with approved single-agonist (semaglutide) and dual-agonist (tirzepatide) therapies. Its cyclic, lipophilic structure is claimed to allow oral dosing without absorption enhancers such as SNAC.

Evidence caveat: The strength of evidence here is limited and should be read cautiously. The company reports a phase I study with dose-dependent weight loss up to ~6% over 28 days and a 13-week phase II study (ClinicalTrials.gov NCT06564753) reporting roughly 13-14% weight loss with mild gastrointestinal effects. These data have been presented mainly as conference abstracts (ADA 2025 abstract 143-OR) and company announcements rather than full peer-reviewed publications, and independent replication is not yet available. There is no marketing approval; claims of efficacy comparable to injectable incretins remain unverified by the wider scientific literature.

Mechanism of Action

The design combines incretin-based appetite suppression and glycaemic control (GLP-1R, GIPR) with glucagon-driven thermogenesis (GCGR), a combination also pursued by other multi-agonists in development, plus an IGF-1R component attributed to the molecule's IGF-1-fragment origin and proposed to protect against the lean-mass loss seen with aggressive caloric restriction. The relative contribution and balance of each receptor's activation in humans has not been independently characterised in the peer-reviewed literature.

Reconstitution Calculator

Safety Profile

Safety Profile: Bioglutide

Common Side Effects

• Nausea and vomiting (most common, ~20-40% incidence, typically dose-dependent and transient)
• Diarrhea or constipation
• Abdominal pain and bloating
• Decreased appetite (intended therapeutic effect in some contexts)
• Injection site reactions (redness, swelling, itching)
• Headache and dizziness
• Fatigue

Serious Adverse Effects

• Pancreatitis: Acute pancreatitis reported with GLP-1 receptor agonists; discontinue if suspected (severe abdominal pain radiating to back)
• Thyroid C-cell tumors: Boxed warning (class effect for GLP-1 RAs based on rodent studies); clinical relevance in humans uncertain
• Gallbladder disease: Cholelithiasis and cholecystitis reported
• Acute kidney injury: Reported in setting of severe dehydration from GI side effects
• Hypoglycemia: Risk increases when combined with sulfonylureas or insulin
• Diabetic retinopathy complications: Rapid glucose improvement may transiently worsen retinopathy
• Intestinal obstruction: Cases reported, particularly in patients with pre-existing GI conditions

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to the active substance or excipients
• History of pancreatitis
• Severe gastroparesis

Drug Interactions

• Insulin/Sulfonylureas: Increased hypoglycemia risk; dose reduction of these agents may be needed
• Oral medications: Delayed gastric emptying may affect absorption kinetics of co-administered oral drugs
• Warfarin: Monitor INR more frequently when initiating or adjusting dose
• Oral contraceptives: Efficacy may be reduced due to delayed absorption; consider alternative contraception methods
• Acetaminophen: Absorption rate reduced; clinical significance varies

Population-Specific Considerations

• Pregnancy: Contraindicated; discontinue at least 2 months before planned conception (based on long half-life)
• Lactation: Unknown if excreted in breast milk; not recommended during breastfeeding
• Pediatric: Limited safety data; use only under specialist supervision
• Renal impairment: No dose adjustment for mild-moderate; use with caution in severe impairment (eGFR <15)
• Hepatic impairment: Limited data; use with caution in severe hepatic impairment
• Elderly (>75 years): Limited clinical experience; start at lowest dose with careful GI monitoring

Pharmacokinetic Profile